Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: DewDiligence_on_SI who wrote (3099)	9/28/2020 5:42:12 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 3557

Did anyone try Sunitinib to show that it does work in AMD?

To: DewDiligence_on_SI who wrote (3099)	9/28/2020 5:46:42 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 3557

<Twenty-eight percent of patients had incomplete aggregation of GB-102 and had bioabsorbable particles enter the anterior chamber of the eye. This was self-limited and reversible with no long-term sequelae.The incomplete aggregation led to optimization of GB-102 to reduce particle dispersion in the phase 2b ALTISSIMO clinical trial. This randomized study will compare 1 mg and 2 mg doses of GB-102 administered every 6 months to aflibercept every 2 months, with the objective to determine the optimal dose to evaluate in a global phase 3 program.> https://www.retinalphysician.com/issues/2020/march-2020/sustained-release-sunitinib-malate-for-neovascular